ONC-CHAT: Dr. Martine Piccart, 'Absolutely No Advantage' to 2 Years of Trastuzumab

Eight-year follow-up data from the HERA trial confirm that one-year of adjuvant trastuzumab (Herceptin) is better than 2 years -- or none in HER2-positive breast cancer. Bruce Jancin of IMNG Medical ... Author: feeds Added: 09/04/2013
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts